(SV) Stayble Therapeutics senarelägger publicering av årsredovisning 2024 till den 14 maj
May 2025 RegulatoriskStayble Therapeutics AB (“Stayble” eller “Bolaget”) har beslutat att senarelägga publiceringen av bolagets årsredovisning för 2024 på grund av pågående emission.
Bolaget angav tidigare att årsredovisningen skulle publicerats imorgon den 7 maj 2025. Ny publiceringsdag är den 14 maj 2025.
For more information
Andreas Gerward, CEO of Stayble Therapeutics AB
Mail: andreas.gerward@stayble.se
Phone: +46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical pharmaceutical company developing the injection treatment STA363 for lumbar disc herniation (LDH). Stayble’s vision is to offer patients a simple and effective treatment that targets the underlying cause of the patient’s chronic pain and provides lasting pain relief and increased physical function. The treatment is aimed at patients who are not helped by physical therapy and painkillers and is a single injection that is expected to last a lifetime and requires minimal rehabilitation. After convincing data from previous pre-clinical and clinical studies (phase 1b and 2b) in degenerative disc disease, which show a volume reduction of the discs, the Company has successfully completed a phase 1b study for the treatment of herniated discs.
The company’s Certified Adviser is Svensk Kapitalmarknadsgranskning AB.
